secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001437749-24-015686
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma Q1 revenue $8.0M (+50% YoY); acquires PKU GOLIKE; submits NDA for ET-400
--------------------------------------------------------------------------------

- Q1 2024 revenue $8.0M, up 50% YoY; net loss narrowed to $0.8M from $2.7M.
- Acquired U.S. rights to PKU GOLIKE for PKU; market ~$100M; targeting $10M annual sales.
- Submitted NDA for ET-400 (hydrocortisone oral solution); potential approval Q1 2025; peak sales >$50M combined.
- Launched Nitisinone in Feb 2024; $50M market; cross-selling opportunities with Carglumic Acid and PKU GOLIKE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924015686/0001437749-24-015686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924015686/eton20240426_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-015686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer